

PRAC SIS



TREĆI KONGRES 34. OGRANKA AMERIČKOG KOLEDŽA KARDIOLOGA ZA SRBIJU I REPUBLIKU SRPSKU

THIRD CONGRESS OF THE 34th AMERICAN COLLEGE OF CARDIOLOGY CONSORTIUM CHAPTER OF SERBIA AND REPUBLIC OF SRPSKA

Praktični aspekti i komparativna analiza **ACC/AHA** i
ESC preporuka u Srbiji 2018 (**PRAC SIS 2018**)
*PRactical aspects and comparative analysis of ACC/AHA and
ESC guidelines In Serbia 2018 (PRAC SIS 2018)*

23-24. februar 2018. godina, Hotel M "Best Western", Beograd
February 23-24, 2018, Hotel "M" Best Western, Belgrade

NAUČNI PROGRAM SCIENTIFIC PROGRAMME



34. Ogranak / 34 Chapter



AMERICAN
COLLEGE of
CARDIOLOGY

Osnovano 2015 / Founded 2015



UDRUŽENJE
KARDIOLOGA
REPUBLIKE SRPSKE



Dvostruki mehanizam protiv kardiovaskularnog kontinuuma

Barios®

nebivolol

5 mg

blistar, 3 x 10 tableta

Terminalna
srčana insuficijencija¹

Hipertenzija¹

Kongestivna
srčana insuficijencija¹

Endotelna
disfunkcija¹

Dilatacija
leve komore¹

Ateroskleroza¹

Remodelovanje²

Koronarna
bolest¹

Ožiljak
miokarda¹

Ishemija
miokarda¹

Infarkt
miokarda¹

Koronarna
tromboza¹



Prilikom propisivanja leka prethodno pročitati kompletan tekst Sažetka karakteristika leka Barios. Lek se može izdavati samo uz lekarski recept. Nosilac dozvole i proizvođač HEMOFARM AD VRŠAC, Beogradski put bb, Vršac, Republika Srbija. Broj rešenja: 515-01-03764-14-001 od 13.04.2016 za lek Barios®, tablete, 30 x (5mg)
Datum poslednje revizije teksta SmPC-a: Mart, 2016.

1. Nitric oxide mechanisms of nebivolol Angelo Maffei and Giuseppe Lembo; Ther Adv Cardiovasc Dis (2009) 3(4)317-327
2. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy Stefano Ghio, Giulia Magrini, Alessandra Serio, Catherine Klersy, Alessandro Fucili, Aleksandar Ronaszeki, Pal Karpati, Giacomo Mordenti, Angela Capriati, Philip A. Poole - Wilson, and Luigi Tavazzi European Heart Journal(2006) 27, 562-568 doi

svako dobro Hemofarm

član STADA grupe

PRACSIS

2018



**TREĆI KONGRES 34. OGRANKA AMERIČKOG
KOLEDŽA KARDIOLOGA ZA SRBIJU
I REPUBLIKU SRPSKU**

**THIRD CONGRESS OF THE 34th AMERICAN COLLEGE
OF CARDIOLOGY CONSORTIUM CHAPTER
OF SERBIA AND REPUBLIC OF SRPSKA**

**Praktični aspekti i komparativna analiza ACC/AHA i
ESC preporuka u Srbiji 2018 (PRAC SIS 2018)**
*PRactical aspects and comparative analysis of ACC/AHA and
ESC guidelines In Serbia 2018 (PRAC SIS 2018)*

34. Ogranak / 34 Chapter



AMERICAN
COLLEGE *of*
CARDIOLOGY

Osnovano 2015 / Founded 2015



UDRUŽENJE
KARDIOLOGA
REPUBLIKE SRPSKE

23-24. februar 2018. godina, Hotel M "Best Western", Beograd
February 23-24, 2018, Hotel "M" Best Western, Belgrade

Organizator: Ogranak Američkog koledža kardiologa za Srbiju i Republiku Srpsku u saradnji sa Udruženjem kardiologa Srbije, Udruženjem kardiologa Republike Srpske, Američkim koledžom kardiologa, Odborom za kardiovaskularnu patologiju Srpske akademije nauka i umetnosti, Medicinskim fakultetom Univerziteta u Beogradu i Akademijom medicinskih nauka Srpskog lekarskog društva

Organizer: *American College of Cardiology Consortium Chapter of Serbia and Republic of Srpska in cooperation with Cardiology Society of Serbia, Cardiology society of Republic of Srpska, American College of Cardiology, Board of cardiovascular pathology Serbian Academy of Sciences and Arts, School of Medicine University of Belgrade, and Academy of Medical Sciences of the Serbian Medical Society*

Organizacioni odbor/Organizational board:

Prof. dr M.A. Nedeljković, Predsednik Ogranka ACC za Srbiju i Republiku Srpsku / *Governor of the ACC Consortium Chapter of Serbia and Republic of Srpska*

Prof. dr D. Vulić, prethodni predsednik Udruženja kardiologa Republike Srpske; Budući Predsednik Ogranka ACC za Srbiju i Republiku Srpsku od 2019 / *Past President of the Cardiology Society of Republic of Srpska; Governor Elect of the ACC Consortium Chapter of Serbia and Republic of Srpska from 2019*

Akademik Prof. dr M. Ostojić, prethodni predsednik Udruženja kardiologa Srbije / *Past President of the Cardiology Society of Serbia*

Prof. dr A. Đorđević Dikić, Predsednik Udruženja kardiologa Srbije / *President of the Cardiology Society of Serbia*

Prof. dr B. Beleslin, prethodni predsednik Udruženja kardiologa Srbije / *Past president of the Cardiology Society of Serbia*

Prof. dr Z. Perišić, prethodni predsednik Udruženja kardiologa Srbije / *Past President of the Cardiology Society of Serbia*

Asist. dr V. Giga, sekretar-blagajnik Udruženja kardiologa Srbije / *Secretary-Treasurer of the Cardiology Society of Serbia*

Počasni odbor/Honorary Board:

Akademik Prof.dr Vladimir Kanjuh

Akademik Prof. dr Miodrag Ostojić

Akademik Prof. Radoje Čolović

Akademik Prof.dr Nebojša Lalić

Akademik Prof. dr Jovan Hadži-Đokić

Doc. dr Sanja Radojević-Škodrić

Prof. dr Pavle Milenković

Prof. dr Milovan Bojić

Doc. dr Milika Ašanin

Sponzori/Sponsors: Astra Zeneca, Bayer, Hemofarm, PharmaSwiss, Alkaloid, Amicus, Merck, Pfizer

Kotizacija: 50 evra (+PDV) u dinarskoj protivvrednosti

Registration fee: 50 euros (+VAT) in dinar value

Učesnici: kardiolozi i internisti koji se bave kardiologijom iz Srbije i regiona

Target audience: *Cardiologists and internal medicine specialists that manage cardiology patients from Serbia and the region*

Akreditacija: Koordinator: Dragana Bačić

(emil/tel: dragana.bacic@gmail.com; 066-8301-918)

“Praktični aspekti i komparativna analiza ACC/AHA i ESC preporuka u Srbiji 2018 (PRACSIS 2018)” je odlukom Zdravstvenog saveta Srbije broj 153-02-3452/2017-01 od 18.11.2017. godine, pod evidencionim brojem A-1-2385/17, akreditovan na sledeci nacin: **broj bodova za predavače 8, a za pasivno učešće 4.**

Accreditation: *Coordinator: Dragana Bačić (emil/tel: dragana.bacic@gmail.com; 066-8301-918) „Practical aspects and comparative analysis of ACC/AHA and ESC guidelines In Serbia 2018 (PRACSIS 2018)” is accredited by the Serbian Health Council with **8 CME credits for lecturers and 4 CME credits for passive participants.***

Kotizacije: (Zivka Milicevic email/tel: zivka.milicevic@gmail.com; 064-285-14-38)

Registration fee: (Zivka Milicevic email/tel: zivka.milicevic@gmail.com; 064-285-14-38)

Rezervacije smeštaja – Rubicon tarvel

(Mirko Levajac, email/tel: kongresi@rubicontravel.rs; 060-4141540)

Accommodation: *Accommodation reservation Hotel M BestWestern*

(Mirko Levajac email/phone: kongresi@rubicontravel.rs; 060-4141540)

MedTech Europe Code of Ethical Business Practice:

“THIRD CONGRESS OF THE 34th AMERICAN COLLEGE OF CARDIOLOGY CONSORTIUM CHAPTER OF SERBIA AND REPUBLIC OF SRPSKA” is **COMPLIANT** with the MedTech Europe Code of Ethical Business Practice. More details are available on:

<https://www.ethicalmedtech.eu/medtech-apps/cvs/view-event/EMT8117>



(San Dijego, USA, 64. ACC Kongres, s desna na levo: Prof. dr Milan A. Nedeljković – prvi Guverner novoosnovanog 34. ACC Ogranka za Srbiju i Republiku Srpsku, Prof. dr Duško Vulić, Prof. dr Branko Beleslin)

Poštovane kolegice i kolege,

Veliko mi je zadovoljstvo da Vas pozdravim na početku Trećeg kongresa 34. Ogranka Američkog koledža kardiologa za Srbiju i Republiku Srpsku, koji će se održati 23-24. februara 2018. godine, u hotelu M "Best Western" u Beogradu.

Prvu ideju za osnivanje ACC Ogranka za Srbiju i Republiku Srpsku dao je Nathan Wong, kardiolog iz Irvajna (Kalifornija, SAD) tokom 62. ACC kongresa koji je održan u San Francisku 2013. godine, što je svesrdno podržao William Zoghbi iz Hjustona (Teksas, SAD) koji je te godine bio predsednik Američkog koledža kardiologa. Tokom 2014. godine ispunili smo sve formalne uslove za formiranje Ogranka (među njima je najvažniji da Ogranak broji najmanje 20 članova) i pristupni pregovori koje su sa ACC Bordom vodili Milan Nedeljković i Duško Vulić su održani na 63. ACC kongresu u Vašingtonu 2014. godine. 34. Ogranak Američkog koledža kardiologa za Srbiju i Republiku Srpsku (ACC Consortium Chapter for Serbia and Republic of Srpska) je osnovan početkom 2015. godine, a promovisan 15. marta 2015. godine u San Dijegu na 64. kongresu Američkog koledža kardiologa. Ovaj Ogranak je formiran sa ciljem unapređenja saradnje i povezivanja Američkog koledža kardiologa sa Udruženjem kardiologa Srbije i Udruženjem kardiologa Republike Srpske. Prvi vidovi ove saradnje su bili realizovani kroz organizaciju zajedničkih sesija na XX i XXI Kongresu Udruženja kardiologa Srbije održanom na Zlatiboru 2015. i 2017. godine, IV Kongresu kardiologa Republike Srpske u Banji Vrućici 2016. godine, 65. Kongresu Američkog koledža kardiologa održanom u Čikagu u martu 2016. godine, 66. Kongresu Američkog koledža kardiologa održanom u Vašingtonu u martu 2017. godine, kao i Prvom i Drugom kongresu PRACSIS 2016. i 2017.

Teme Trećeg kongresa biće prikaz i analiza 4 nova ESC vodiča (za STEMI, perifernu arterijsku bolest, bolest srčanih zalistaka i dvojni antitrombocitnu terapiju) i 2 nova ACC/AHA vodiča (za sinkopu i arterijsku hipertenziju). Predavači i moderatori će biti najistaknutiji kardiolozi Udruženja kardiologa Srbije i Udruženja kardiologa Republike Srpske.

S poštovanjem,

Milan Nedeljković
Prof. dr Milan A. Nedeljković

Prvi predsednik 34. Ogranka Američkog koledža kardiologa za Srbiju i Republiku Srpsku

Dear Colleagues,

It is my great pleasure to greet you at the beginning of the Third Congress of the 34th American College of Cardiology Consortium Chapter of Serbia and Republic of Srpska, which will be held on February 23-24, 2018, at Hotel M "Best Western" in Belgrade.



First idea for establishing the ACC Chapter for Serbia and Republic of Srpska was introduced by Nathan Wong, cardiologist from Irvine (California, USA), during 62nd ACC Congress held in San Francisco in 2013. This was supported by William Zoghbi from Houston (Texas, USA), who was the president of the ACC at that time. During 2014 we fulfilled all formal criteria for the formation of ACC Chapter (most important was to have at least 20 Fellows of the ACC), and negotiations with ACC Board, led by Milan Nedeljkovic and Dusko Vulic, took place in Washington during 63rd ACC Congress in 2014.

34th Chapter of the American College of Cardiology of Serbia and the Republic of Srpska was founded in early 2015 and was promoted on March 15, 2015 in San Diego at the 64th Congress of the American College of Cardiology. This Chapter was founded with the aim of improving cooperation and connection with the American College of Cardiology, Cardiology Society of Serbia, and Cardiology Society of the Republic of Srpska. The first steps of this cooperation were realized through the organization of joint sessions at the 20th and 21st Congress of the Cardiology Society of Serbia that was held on Zlatibor in 2015 and 2017, 4th Congress of the Republic of Srpska Society of Cardiology in Spa Vrucica 2016, 65th Congress of the American College of Cardiology held in Chicago in March 2016, 66th Congress of the American College of Cardiology held in Washington in March 2017, and during PRACSIS 2016 and 2017 meetings.

The main topic of Third Congress will be the analysis of the 4 most recent ESC clinical guidelines (for STEMI, peripheral artery disease, valvular heart disease, and dual antiplatelet therapy) and 2 ACC/AHA guidelines (for syncope and arterial hypertension). Speakers and moderators will be the most prominent cardiologists of the Cardiology Society of Serbia and the Cardiology Society of Republic of Srpska.

I wish you a successful meeting.

Milan Nedeljkovic

Professor Milan A. Nedeljkovic
First Governor of the 34th ACC Consortium
Chapter of Serbia and Republic of Srpska

08:00-08:30

OTVARANJE KONFERENCIJE / OPENING CEREMONY

Predsedništvo/*Chairpersons*: **M.A. Nedeljković (Beograd)**, V. Kanjuh (Beograd), M. Ostojić (Beograd), R. Čolović (Beograd), N. Lalić (Beograd), J. Hadži-Đokić (Beograd), P. Milenković (Beograd), M. Bojić (Beograd), M. Ašanin (Beograd), D. Vulić (Banja Luka), A. Đorđević Dikić (Beograd), B. Beleslin (Beograd), Z. Perišić (Niš)

08:30-09:00

Uvodno predavanje / Introductory lecture

ŽIVOT NEUMITNO IDE DALJE: NAJBOLJE OSTVARENO U TEŠKIM USLOVIMA I NAJLOŠIJE OCENE ZA NAJBOLJA OSTVARENJA – LIČNI STAV

THE SHOW MUST GO ON: THE BEST OF MY WORST AND THE WORST FOR MY BEST – PERSONAL PERSPECTIVE

M. Ostojić (Beograd)

09:00-10:30 **AKUTNI INFARKT MIOKARDA SA ELEVACIJOM ST SEGMENTA
ST-SEGMENT ELAVATION ACUTE MYOCARDIAL INFARCTION**

Moderatori/Moderators: **M. Ostojić, S. Stojković, I. Srdanović, R. Lasica**, M. Ašanin, V. Miloradović, P. Mitrović, V. Vukčević, R. Babić, M. Radovanović, S. Juričić, S. Živković

09:00-09:10 **Uvod**

Introduction

P. Mitrović (Beograd)

09:10-09:35 **Prikaz prvog slučaja i stručni komentar u kontekstu ESC preporuka 2017**

Case presentation and comment related to ESC 2017 guidelines
S. Juričić (Beograd)

09:35-10:00 **Prikaz drugog slučaja i stručni komentar u kontekstu ESC preporuka 2017**

Case presentation and comment related to ESC 2017 guidelines
R. Lasica (Beograd)

10:00-10:25 **Prikaz trećeg slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Case presentation and comment related to ESC 2017 guidelines
M. Trajković (Sremska Kamenica)

10:25-10:30 **Okrugli sto, diskusija i zaključak**
Round table, discussion, and conclusion
S. Stojković (Beograd)

10:30-11:15

**SIMPOZIJUM FARMACEUTSKE INDUSTRIJE - ASTRA ZENECA
DA LI JE NSTE-AKS POTCENJEN U ODNOSU NA STEMI INFARKT?**

Moderatori: M.A. Nedeljković (Beograd), S. Stojković (Beograd)

11:15-12:00

**SIMPOZIJUM FARMACEUTSKE INDUSTRIJE - PFIZER
ELIQUIS – SAVREMENA ANTIKOAGULANTNA TERAPIJA –
ATRIJALNA FIBRILACIJA**

Moderator i predavač: T.S. Potpara (Beograd)

Izazovi u antikoagulantnoj terapiji

T. Jozić (Beograd)

12:30-14:00

PERIFERNA ARTERIJSKA BOLEST / PERIPHERAL ARTERIAL DISEASE

Moderatori/Moderators: **D. Vasić**, M. Marković, D. Sagić, M. Dragaš, B. Beleslin, A. Đorđević-Dikić, M. Stanković

12:30-12:50 **Uvod i prikaz prvog slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Introduction and case presentation and comment related to ESC 2017 guidelines
D. Vasić i saradnici (Beograd)

12:50-13:10 **Prikaz drugog slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Case presentation and comment related to ESC 2017 guidelines
M. Marković (Beograd)

13:10-13:30 **Prikaz trećeg slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Case presentation and comment related to ESC 2017 guidelines
M. Dragaš (Beograd)

13:30-14:00 **Okrugli sto, diskusija i ključne poruke**
Round table, discussion, and key messages
M. Marković (Beograd)

14:00-14:45

SIMPOZIJUM FARMACEUTSKE INDUSTRIJE - HEMOFARM PARAVANO – ROSUVASTATIN U FOKUSU

M. Petakov (Beograd)

14:45-15:30

SIMPOZIJUMI FARMACEUTSKE INDUSTRIJE TAVI – STRATEGIJA RAZVOJA U SRBIJI

Moderator: M.A. Nedeljković (Beograd)

Karakteristike i unapređenja poslednje generacije Evolute R valvule

M.A. Nedeljković (Beograd)

Pregled najnovijih kliničkih studija

B. Beleslin (Beleslin)

Dosadašnja iskustva u primeni TAVI tehnologije

M. Bunc (Ljubljana)

16:00-17:30

BOLEST SRČANIH ZALISTAKA VALVULAR HEART DISEASE

Moderatori/Moderators: **B. Obrenović-Kirćanski, D. Kalimanovska-Oštrić, M. Petrović, Lj. Jovović, I. Nedeljković, T. Kovačević-Preradović, N. Marković, V. Giga, M. Banović, A. Stojšić-Milosavljević, I. Burazor**

16:00-16:10 **Uvod**

Introduction

B. Obrenović-Kirćanski (Beograd)

- 16:10-16:30 **Prikaz prvog slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Case presentation and comment related to ESC guidelines 2017
D. Kalimanovska-Oštrić, I. Rakočević (Beograd)
- 16:30-16:50 **Prikaz drugog slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Case presentation and comment related to ESC 2017 guidelines
A. Stojšić-Milosavljević (Sremska Kamenica)
- 16:50-17:10 **Prikaz trećeg slučaja i stručni komentar u kontekstu ESC preporuka 2017**
Case presentation and comment related to ESC 2017 guidelines
I. Burazor, B. Obrenović-Kirćanski (Beograd)
- 17:10-17:30 **Okrugli sto, diskusija i zaključak**
Round table, discussion, and conclusion
B. Obrenović-Kirćanski (Beograd)

09:00-10:30

DVOJNA ANTITROMBOCITNA TERAPIJA U KORONARNOJ BOLESTI

DUAL ANTIPLATELET THERAPY IN CORONARY ARTERY DISEASE

Moderatori/Moderators: **S. Obradović, M. Tomašević, S. Stojković,**
S. Aleksandrić, M. Tešić, M. Dikić, M. Živković, V. Dedović

09:00-09:10

Uvod

Introduction

S. Obradović (Beograd)

09:10-09:30

Prikaz prvog slučaja i stručni komentar u kontekstu ESC preporuka 2017

Case presentation and comment related to ESC 2017 guidelines

Z. Jović (Beograd)

09:30-09:50

Prikaz drugog slučaja i stručni komentar u kontekstu ESC preporuka 2017

Case presentation and comment related to ESC 2017 guidelines

S. Aleksandrić (Beograd)

09:50-10:10

Prikaz trećeg slučaja i stručni komentar u kontekstu ESC preporuka 2017

Case presentation and comment related to ESC 2017 guidelines

M. Spasić (Beograd)

10:10-10:30

Okrugli sto, diskusija i zaključak

Round table, discussion, and conclusion

S. Obradović (Beograd)

10:30-11:15

SIMPOZIJUM FARMACEUTSKE INDUSTRIJE - BAYER PRAKTIČNI ASPEKTI PRIMENE LEKA XARELTO®

Moderator: T.S. Potpara (Beograd)

Prikaz slučaja

S. Tadić (Sremska Kamenica)

Prikaz slučaja

V. Ristić (Beograd)

Prikaz slučaja

M. Dobrić (Beograd)

11:15-12:00

SIMPOZIJUM FARMACEUTSKE INDUSTRIJE - MERCK PRIMENA CONCOR-A U PRAKSI INVAZIVNIH I NEINVAZIVNIH KARDIOLOGA

Moderator: M.A. Nedeljković (Beograd)

Mesto Concor-a u lečenju bolesnika sa stabilnom koronarnom bolešću

V. Giga (Beograd)

Concor nakon perkutanih koronarnih intervencija

M.A. Nedeljković (Beograd)

12:15-13:45

ARTERIJSKA HIPERTENZIJA – ŠTA NAM DONOSE NOVE AMERIČKE PREPORUKE ARTERIAL HYPERTENSION – WHAT IS NEW IN 2017 AMERICAN GUIDELINES

Moderatori/Moderators: **M. Deljanin-Ilić**, V. Stojanov, D. Simić, D. Lović, N. Tasić,
D. Simonović

12:15-12:20 **Uvod**

M. Deljanin-Ilić (Niška Banja)

12:20-12:40 **Prikaz prvog slučaja i stručni komentar u kontekstu
ACC preporuka 2017**

Case presentation and comment related to ACC guidelines 2017

D. Simonović (Niška Banja)

12:40-13:00 **Prikaz drugog slučaja i stručni komentar u kontekstu ACC
preporuka 2017 – arterijska hipertenzija kod starih osoba**

***Case presentation and comment related to ACC 2017 guidelines
– arterial hypertension in elderly patients***

B. Ilić (Niška Banja)

13:00-13:20 **Prikaz trećeg slučaja i stručni komentar u kontekstu ACC preporuka 2017 – bolesnik sa hipertenzijom i koronarnom bolešću**
Case presentation and comment related to ACC 2017 guidelines – patient with hypertension and coronary artery disease
D. Lović (Niš)

13:20-13:45 **Okrugli sto i diskusija**
Round table and discussion
M. Deljanin-Ilić (Niška Banja)

14:00-15:30

2017 ACC/AHA/HRS VODIČ ZA EVALUACIJU I LEČENJE BOLESNIKA SA SINKOPOM
2017 ACC/AHA/HRS GUIDELINE FOR THE EVALUATION AND MANAGEMENT OF PATIENTS WITH SYNCOPE

Moderatori/Moderators: **D. Kojić, N. Mujović, V. Mitov, A. Kocijančić, D. Unčanin, A. Jolić, M. Marinković, V. Kovačević**

14:00-14:10 **Uvod**
Introduction
D. Kojić (Beograd)

14:10-14:30 **Prikaz prvog slučaja i stručni komentar u kontekstu ACC/AHA/HRS preporuka 2017**
Case presentation and comment related to ACC/AHA/HRS 2017 guidelines
N. Mujović (Beograd)

14:30-14:50 **Prikaz drugog slučaja i stručni komentar u kontekstu ACC/AHA/HRS preporuka 2017**
Case presentation and comment related to ACC/AHA/HRS 2017 guidelines
V. Mitov (Zaječar)

14:50-15:10 **Prikaz trećeg slučaja i stručni komentar u kontekstu ACC/AHA/HRS preporuka 2017**
Case presentation and comment related to ACC/AHA/HRS 2017 guidelines
D. Kojić (Beograd)

15:10-15:30 **Okrugli sto, diskusija i zaključak**
Round table, discussion, and conclusion
N. Mujović (Beograd)

15:30

ZAVRŠNE NAPOMENE

CLOSING REMARKS

Predsedništvo/*Chairpersons*: M.A. Nedeljković (Beograd), D. Vulić (Banja Luka),
B. Beleslin (Beograd), A. Đorđević Dikić (Beograd), Z. Perišić (Niš)

 **TOREZ**[®]
atorvastatin

Zyglip[®]
fenofibrat

Biprez[®]
bisoprolol

AMLODIPIN
Alkaloid

Indapamid SR
Alkaloid[®]

 **LOTAR**
losartan

SKOPRYL[®]
lizinopril




SKOPRYL[®]
lizinopril hidrohlorotiazid
PLUS

BioKrill
Active[®]



ALKALOID
BEOGRAD



 **trinomia**
acetilsalicilna kiselina • atorvastatin • ramipril

Terapija, komplijansa i komfor
u jednoj kapsuli

AMICUS 
Modern Medicines for All

Prva 'polypill' formulacija sa
lekovima izbora u sekundarnoj
kardiovaskularnoj prevenciji



 **ferrer**

Broj i datum dozvole: Trinomia, kapsula tvrša, 28 x (20 mg/100 mg/2,5 mg): 515-01-01539-15-001, 27.05.2016.
Trinomia, kapsula tvrša, 28 x (20 mg/100 mg/5 mg): 515-01-01540-15-001, 27.05.2016.
Trinomia, kapsula tvrša, 28 x (20 mg/100 mg/10 mg): 515-01-01541-15-001, 27.05.2016.
Nosilac dozvole: AMICUS SRB d.o.o., Milorada Jovanovića 9, Beograd

Samo za stručnu javnost

CoreValve[®] Evolut[™] R


TAVI System



SIMPATIČKA HIPERAKTIVNOST


Pazite na otkucaje

Samo* za stručnu javnost.



MERCK

BINEVOL[®]
NEBIVOLOL



SNAGA DVOJNOG MEHANIZMA

BINEVOL[®] je β -blokator treće generacije sa dvostrukim mehanizmom dejstva:

- Visokoselektivna β_1 -blokada
- Azot-oksídom (NO) posredovana vazodilatacija

INDIKACIJE

- Arterijska hipertenzija
- Hronična srčana insuficijencija

Referenca: Sažetak karakteristika leka, oktobar 2009

Samo za stručnu javnost

Lek se može izdavati samo uz lekarski recept

Broj i datum dobijanja dozvole za lek ili datum poslednje obnove ili dopune dozvole za lek:

Binevol[®] 30 x 5 mg, tableta: 515-01-02264-14-001 20.04.2015. JKL 1107633

PHARMASWISS
A Valerius Pharmaceuticals International, Inc. company



Eliquis[®]
apixaban





BRILIQUE®

tikagrelor

PACIJENTIMA
SA IM*
SAMO
DOBRO
NIJE
DOVOLJNO
DOBRO




AstraZeneca 

Predstavništvo AstraZeneca UK Ltd.
Bulevar Vojvode Mišića 15, 11000 Beograd
Tel + 381 11 3336 900 • Fax + 381 11 3336 901

*IM - infarkt miokarda
Broj dozvole za Brilique 56 x 90 mg:
515-01-04425-16-001 od 30.08.2017.
Detaljne informacije dostupne na zahtev.
SAMO ZA STRUČNU JAVNOST

Poverenje iz dokaza i iskustva svetske kliničke prakse¹⁻¹⁵



Samo za stručnu javnost

▼ Ovaj lek je pod dodatnim praćenjem. Time se omogućava brzo otkrivanje novih bezbednosnih informacija. Zdravstveni radnici treba da prijave svaku sumnju na neželjene reakcije na ovaj lek.

*Ukupan broj pacijenata u svetu, od datuma prve registracije leka do decembra 2015.

NOAK, ne-vitamin K antagonisti oralni antikoagulansi

Literatura: 1. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. *N Engl J Med.* 2011;365(10):883-91. 2. Hori M., Matsumoto M., Tanahashi N. et al. Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation. *Circ J.* 2012;76(9):210-11. 3. Prins M.H., Lensing A.W.A., Bauersachs R. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. *Thrombosis J.* 2013;11(1):21. 4. Bauersachs R.M., Lensing A.W.A., Prins M.H. et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. *Thrombosis J.* 2014;12:25. 5. Prins M.H., Lensing A.W.A., Brighton T.A. et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. *Lancet Haematol.* 2014;1(1):e37-e46. 6. Buller H.R., Prins M.H., Lensing A.W.A. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med.* 2012;366(14):1287-97. 7. Bauersachs R., Berkowitz S.D., Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med.* 2010;363(26):2499-510. 8. Turpie A.G.G., Lassen M.R., Eriksson B.I. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. *Thromb Haemost.* 2011;105:444-53. 9. Camm J., Amarencio P., Haas S. et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J.* 2016; 37(14):1145-530. 10. Hecker J., Marten S., Keller L. et al. Effectiveness and safety of Rivaroxaban therapy in daily care patients with atrial fibrillation. Results from the Dresden NOAC Registry. *Thromb Haemost.* 2016;115 [Epub ahead of print]. 11. Tamayo S., Peacock F., Patel M.R. et al. Characterizing major bleeding in patients with non-valvular atrial fibrillation: A pharmacovigilance study of 27,467 patients taking rivaroxaban. *Clin Cardiol.* 2015;38(2):63-8. 12. Coleman C., Antz M., Ehken B. et al. Real-Life Evidence of stroke prevention in patients with atrial fibrillation - The RELIEF study. *Int J Cardiol.* 2016;203:882-4. 13. Coleman C.I., Antz M., Simard E. et al. Real-world Evidence on Stroke prevention in patients with Atrial Fibrillation in the United States. The REVISIT-US Study. *Intern Card Electrophysiol.* 2016;45(3):232-333. Special program and abstract issue of the 12th Annual Congress of the European Cardiac Arrhythmia Society (ECAS). April 17-19, 2016, Paris, France. 14. Ageno W., Mantovani L.G., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. *Lancet Haematol.* 2016;3(1):e12-e21. 15. Turpie A.G.G., Haas S., Kreutz R. et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. *Thromb Haemost.* 2014;111(1):94-102. 16. Xarelto® Sažetak karakteristika leka 15 i 20mg, januar 2016. 17. Xarelto® Sažetak karakteristika leka 10mg, februar 2016. 18. Xarelto® Sažetak karakteristika leka 2,5mg, februar 2016. 19. Calculation based on IMS Health MIDAS. Database: Monthly Sales December 2015. 20. IMS Health MIDAS-Xarelto Patient Number Dec 2015.

Molimo Vas da pre propisivanja pročitate Sažetak karakteristika leka.

Xarelto 2,5 mg:

Način izdavanja leka: Lek se može upotrebljavati u stacionarnoj zdravstvenoj ustanovi; izuzetno lek se može izdavati i uz lekarski recept, u cilju nastavka terapije kod kuće, što mora biti naznačeno i oверeno na poledini recepta.

Broj i datum dozvole:

Xarelto, film tablete, 56x (2,5mg): 515-01-04847-13-001 od 27.05.2014.

Xarelto 10 mg

Način izdavanja leka: Lek se može upotrebljavati u stacionarnoj zdravstvenoj ustanovi; izuzetno lek se može izdavati i uz lekarski recept, u cilju nastavka terapije kod kuće, što mora biti naznačeno i oверeno na poledini recepta.

Broj i datum dozvole:

Xarelto®, film tablete, 10x(10mg): 515-01-05366-13-001 od 15.01.2014.; Xarelto®, film tablete, 30x(10mg): 515-01-05367-13-001 od 15.01.2014.

Xarelto 15mg i 20mg:

Način izdavanja leka: lek se može izdavati samo uz lekarski recept.

Broj i datum dozvole:

Xarelto®, film tablete, 28x(15mg): 515-01-3983-12-001 od 18.04.2013.; Xarelto®, film tablete, 28x(20mg): 515-01-3985-12-001 od 18.04.2013.; Xarelto®, film tablete, 42x(15mg): 515-01-3984-12-001 od 18.04.2013.

Notisilac dozvole: Bayer d.o.o., Omladinskih brigada 88b, 11070 Beograd
Broj odobrenja ALIM: 515-08-00195-16-001

**Najpropisvaniji NOAK u svetu,
 18 miliona pacijenata*
 u 5 indikacija¹⁶⁻²⁰**